Search results for: psoriasis

FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications

Michele B. Kaufman, PharmD, BCGP | May 29, 2019

The FDA has approved rizankixumab to treat adults with plaque psoriasis and added boxed warnings to sleep medications…

Peripheral Manifestations of Spondyloarthritis

Lara C. Pullen, PhD | May 29, 2019

A recent study evaluated the factors associated with the presence of peripheral manifestations of spondyloarthritis (SpA), which affects more than half of patients with SpA. Researchers found that being older, HLAB27 negative and having a history of psoriasis were associated with these symptoms…

British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars

Allison Martell & Allison Lampert | May 29, 2019

TORONTO/MONTREAL (Reuters)—The Canadian province of British Columbia said on May 28 that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million) over three years. The new policy from the province’s PharmaCare program targets Johnson & Johnson’s…

Cardiovascular Risk in Rheumatoid Arthritis: Pathogenesis, Screening & Prevention

Mary Beth Nierengarten | May 18, 2019

SNOWMASS VILLAGE, COLO.—Even in the era of treat to target, cardiovascular disease risk remains elevated and is a major source of mortality and morbidity in patients with rheumatoid arthritis (RA). Screening and management of cardiovascular risk in these patients is critical to ensure these patients are identified and treated. At the 2019 ACR Winter Rheumatology…

Psoriatic Arthritis: A Look Back at Moll & Wright’s Landmark 1973 Paper

Ruth Jessen Hickman, MD | May 17, 2019

Psoriatic arthritis came to be viewed as a distinct disease entity with specific clinical features, genetics and pathophysiology only gradually. One important historic development in this transition was a 1973 paper written by a pair of researchers out of Leeds, England: John M. Moll, BSc, DM, and Verna Wright, MD, FRCP.1 Here we discuss the…

Health Canada Approves Certolizumab Pegol & NICE Issues Guidance for Certolizumab Pegol

Michele B. Kaufman, PharmD, BCGP | May 7, 2019

Certolizumab pegol has been approved in Canada for treating adults with plaque psoriasis. The U.K. has also issued its final guidance for the treatment’s use…

FDA Approves Certolizumab Pegol for Treating Non-Radiographic Axial SpA

Michele B. Kaufman, PharmD, BCGP | April 30, 2019

Certolizumab pegol is now FDA approved to treat adults with active non-radiographic axial spondyloarthritis…

Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Mary Choy, PharmD, BCGP, FASHP | April 15, 2019

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

State Step Therapy Laws: Not All Are Created Equal

From the College | April 8, 2019

Step therapy reform has been a hot topic and major focus of the ACR’s advocacy activity in states this legislative session. Washington, Oregon, Wisconsin and Florida are all considering step therapy bills that stand good chance of passing this legislative year. Virginia and Georgia have already passed step therapy laws. When these two new laws…

FDA Approves Guselkumab Injector

Michele B. Kaufman, PharmD, BCGP | March 20, 2019

The FDA has approved a single-press, self-injection device for a 100-mg dose of guselkumab for adults with moderate to severe plaque psoriasis…